Published in Gene Therapy Weekly, May 20th, 2004
"The carboxyl-terminal modulator protein (CTMP) has been identified as a negative regulator of protein kinase B/Akt. Aberrant Akt signaling is frequently observed in glioblastomas, the most common and most malignant glial brain tumors. Because loss of CTMP function and/or expression may remove the inhibitory effects on Akt and promote tumorigenesis," 93 primary glioblastomas and nine glioblastoma cell lines" were studied "for CTMP deletion, mutation, promoter hypermethylation, and mRNA expression," wrote scientists in the Journal of the National Cancer Institute.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.